Capital Research Global Investors Sells 372,720 Shares of Johnson & Johnson $JNJ

Key Points

• Capital Research Global Investors cut its Johnson & Johnson stake by 11.0% in Q3, selling 372,720 shares and leaving 3,014,727 shares valued at about $559 million (≈0.13% of the company).
• Recent regulatory wins — FDA approval of the TECVAYLI + DARZALEX FASPRO combo and EU expansion for Akeega — could boost J&J’s oncology revenue and helped revive investor interest; analysts collectively rate the stock a Moderate Buy with an average price target of $234.87.
• Insiders sold roughly 30,142 shares (~$7.36 million) in the last quarter including two EVP sales, while institutional investors own about 69.55% of the stock; J&J pays a $1.30 quarterly dividend (2.1% yield).

Capital Research Global Investors reduced its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,014,727 shares of the company's stock after selling 372,720 shares during the quarter. Capital Research Global Investors owned approximately 0.13% of Johnson & Johnson worth $558,991,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Abich Financial Wealth Management LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at about $26,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at about $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after buying an additional 72 shares during the last quarter. Finally, Compass Financial Services Inc grew its holdings in shares of Johnson & Johnson by 707.1% in the third quarter. Compass Financial Services Inc now owns 226 shares of the company's stock valued at $42,000 after acquiring an additional 198 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Insider Transactions at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company's stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent analyst reports. UBS Group reiterated a "buy" rating on shares of Johnson & Johnson in a report on Monday, January 5th. Loop Capital set a $220.00 target price on Johnson & Johnson in a research note on Tuesday, January 27th. Weiss Ratings reissued a "buy (b)" rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Daiwa Securities Group raised their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an "outperform" rating in a report on Thursday, January 29th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average price target of $234.87.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $243.75 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The company's fifty day moving average price is $229.80 and its 200-day moving average price is $205.27. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The firm has a market capitalization of $587.41 billion, a price-to-earnings ratio of 22.06, a PEG ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion during the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson's payout ratio is presently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.